Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Lifesciences announces completion of Enrolment for Phase II clinical trial of Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS). Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of the post results earnings call held on May 17, 2024 Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from USFDA for Theophylline Extended-Release Tablets, 300 mg and 450 mg. Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Copy of newspaper publication Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Investor call audio link Zydus Lifesciences Ltd - 532321 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report for the financial year March 31, 2024 Q4FY24 Quarterly & FY24 Annual Result Announced for Zydus Lifesciences Ltd.
Pharmaceuticals company Zydus Lifesciences announced Q4FY24 & FY24 results: Q4FY24 Financial Highlights: Revenue from operations was Rs 55,338 million, up 10% over last year. Research & Development (R&D;) investments for the quarter stood at Rs 3,516 million (6.4% of revenues). EBITDA for the quarter was Rs 16,305 million, up 30% YoY. EBITDA margin for the quarter stood at 29.5%, an improvement of 440 bps on a YoY basis. Net Profit for the quarter was Rs 11,823 million, up 299% YoY. Capex (organic) for the quarter was Rs 2,126 million FY24 Financial Highlights: Revenue from operations was Rs 1,95,474 million, up 13% over last year. Research & Development (R&D;) investments stood at Rs 13,096 million (6.7% of revenues). EBITDA was Rs 53,843 million, up 40% YoY. EBITDA margin stood at 27.5%, an improvement of 510 bps over the previous year. Net Profit was Rs 38,595 million, up 97% YoY. Capex (organic) for the year was Rs 8,628 million. Net Debt to Equity ratio as on 31st March, 2024 was -0.04x while Net Debt to EBITDA stood at -0.16x at the end of March, 2024. Net Cash (negative Net Debt) as on March 31st, 2024 was Rs 8,561 million. Dr. Sharvil Patel, Managing Director, said, "We are happy to close the year on a strong note, driven by robust performance across our businesses. Our relentless focus on patient centricity, operational efficiency, strategic investments, and execution of our diversified product portfolio continues to pay off, resulting in a significant improvement in profitability as well. We aspire to sustain strong performance in fiscal year 2024-25 with strong revenue growth and strive to improve EBITDA margins further from FY24 levels. This strong performance is a testament to our commitment to creating long-term value for our stakeholders, and we are wellpositioned for future growth and innovation" Result PDF Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release for the financial results for the quarter and year ended on March 31, 2024 Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation 